{
    "nctId": "NCT02017496",
    "briefTitle": "Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment",
    "officialTitle": "Safety of Breast Conserving Treatment in Locally Advanced Breast Cancer Receiving Neoadjuvant Treatment",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 18,
    "primaryOutcomeMeasure": "1 The presence of viable tumor cells at the margins and in the mastectomy specimen after conducted breast preserving resection followed by mastectomy in the same procedure",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Patients with locally advanced breast cancer (cT3-4c, N0-3) with tumors \\> 5 cm, as determined by MRI, where the present guidelines include them for neoadjuvant systemic therapy\n* Written informed consent (informed consent document to be approved by the Independent Ethics Committee) prior to study-related procedures and examinations.\n* Female age \\> 18 years\n* Able to comply with the protocol\n* Histologically confirmed adenocarcinoma of the breast\n* American Society of Anesthesiologist's physical status category 1 or 2 before surgery. Category 1 and 2 includes healthy patients and patients with only mild systemic disease, whereas category 3 includes patients with more serious systemic diseases (but still operable).\n\nExclusion criteria:\n\n* Inflammatory breast cancer or diffuse locoregional involvement of the skin\n* Stage IV - metastatic disease\n* Locoregional relapse of earlier breast cancer\n* Inability (irrespective of reason) to receive the recommended neoadjuvant treatment, - as decided by the treating physician.\n* American Society of Anesthesiologist's physical status category 4-5",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}